We studied the distribution of the large hyaluronan-binding proteoglycan versican (also known as PG-M) in human adult tissues using affiity-purified polydonal antibodies that recognize the core protein of the prominent versican splice variants VO and V1. Versican was present in the loose connective tissues of various organs and was often associated with the elastic fiber network. Furthermore, it was localized in most smooth musde tissues and in fibrous and elastic cartilage. Versican staining was also noted in the central and peripheral nervous system, in the basal layer of the epidermis, and on the luminal surface of some glandular epithelia. In blood vessels, versican was present in all three wall layers of veins and elastic arteries. In muscular arteries the immunoreactivity was normally restricted to the tunica adventitia. However, it appeared in the media and the split elastica intema of atheroderotically transformed vessel walls. Our survey of the distribution of versican in normal human tissues now forms the basis for extended studies of potentially aberrant versican expression during pathogenic processes. ( J Histochem Cytochem &:303-312, 19%) 
Introduction
Versican (Dours- Zimmermann and Zimmermann, 1994; Shinomura et al., 1993; Zimmermann and Ruoslahti, 1989) belongs to the growing family of large aggregating proteolgycans that also includes aggrecan (Doege et al., 1987 (Doege et al., , 1991 , neurocan (Rauch et al., 1992) , and brevican (Yamada et al., 1994) . These four proteoglycans (PGs) have been grouped together on the basis of their structural similarities and their capacity to bind to hyaluronan. The interaction with hyaluronan is mediated by a common core protein element localized at the N-terminus of the molecules. Other features shared among the four PGs include EGF-, lectin-, and complement regulatory protein-like modules in the C-terminal region. In contrast to these highly similar domains at either end of the core proteins, little resemblance has been observed in the central glycosaminoglycan (GAG)-carrying portions. In aggrecan this domain is substituted with more than 100 GAG side chains, whereas brevican, neurocan, and versican contain only a few chondroitin sulfate chains. Further variability in the unique middle portions is provided by alternative splicing processes. Recently, we have identified three different splice variants of human venican (VO, VI, and V2) that result from alternative splicing of two large exons (Dours-Zimmermann and Zimmermann, 1994; Naso et al., 1994) . Each of these exons encodes a GAG attachment domain, and these domains have been named GAG-a and GAG-B, respectively. Both of these domains are present in the largest VO isoform of versican. In contrast, versican VI contains only the GAG-P and versican V2 only the GAG-a domain. A fourth versican isoform (V3) lacks both the GAG-a and the GAG-P domain and therefore appears to be devoid of GAG side chains . The calculated molecular weights of the core proteins of the four splice variants amount to 370,493, 262,048, 179,739, and 71,970 for the VO, V1, V2, and V3 isoforms, respectively. At present, only versican VO and V1 have been identified on the protein level, whereas the data for the V2 and V3 splice forms are solely based on RT-PCR experiments. On SDS-PAGE, the two largest and most prominent splice variants VO and VI migrate as a double band in the range above 400 KD after chondroitinase ABC digestion (Dours-Zimmermann and Zimmermann, 1994) .
Large aggregating PGs have been isolated from various cell cultures and tissue sources (reviewed by Heinegird and Oldberg, 1993; KjellCn and Lindahl, 1991) . However, because reagents allowing a distinction between the different hyaluronan-binding PGs have become available only recently, studies of the tissue localization of particular core proteins have been rather scarce. Northern blotting experiments with a limited number of RNA samples have suggested that brevican and neurocan are confined to brain tissues (Yamada et al., 1994; Rauch et al., 1992) . Similarly, aggrecan appears to be mainly expressed in cartilage (for references see Heinegdrd and Oldberg, 1993; KjellEn and Lindahl, 1991) . but it may also be present in sclera, tendon (Morgelin et al., 1989) , and neural tissues (Fryer et al., 1992) . In contrast to these rather restricted expression patterns, versican appears to have a much wider distribution. In adult tissues, versican core proteins have been detected in brain (Perides et al., 1992) , aorta (Yao et al., 1994) , and skin .
The suggested functions of aggregating PGs range from supporting the highly hydrated structure of cartilage tissues (aggrecan) to modulatory roles in cell adhesion, migration, and proliferation (reviewed by Margolis and Margolk, 1993; Wight et al., 1992; Esko, 1991; Ruoslahti, 1989) . Versican interferes in vitro with the attachment of cells to various extracellular matrix components such as collagen I, fibronectin, and laminin (Yamagata et al., 1989) . In vivo, we have observed a close correlation between versican expression and the formation of tissues that act as barriers to migratory neural crest cells and outgrowing axons (Landolt et al., 1995) during embryonic development. In addition to this putative role in the inhibition of cell adhesion, versican may also participate in the control of keratinocyte and dermal fibroblast proliferation (&mermann et al., 1994) .
The association of versican expression with cell migration and proliferation in vivo and its adhesion inhibitory properties in vitro point to a potential role of versican in pathological processes such as tumorigenesis and metastasis. However, before a possibly aberrant expression of versican in tumor matrices can be explored, a detailed immunohistochemical analysis of normal versican distribution in adult tissues must be available for comparative studies. For this purpose, we prepared polyclonal antibodies that recognize the core protein of the two prominent versican splice forms VO and V1 and used them for detection of versican in adult human tissues.
Materials and Methods
Tissues. Tissues were obtained at autopsy (not later than 10 hr post mortem) or from biopsy samples and surgically resected organs of various human patients aged 31-69 years. For cryopreservation, tissues were submerged in Hanks solution and snap-frozen in liquid nitrogen. The samples were stored at -70% until use.
Antibodies Against Human Versican VO and V1. Polyclonal antibodies directed against the C-terminal portion of the GAG+ domain were generated as previously described in detail (anti-D; Zimmermann et al., 1994) . Briefly, a core protein portion unique for human versican was prepared in a bacterial expression system (Stiiber et al., 1990) . The obtained fusion protein included at its N-terminus a polyhistidine stretch, which allowed a onestep purification on a metal-chelating affinity column charged with Ni2' (Ni2'-NTA agarose; Qiagen, Dusseldorf, Germany). New Zealand White rabbits were immunized with the isolated fusion protein. The crude antiserum was diluted 1:10 with PBS, run through a bacterial control extract column to remove antibodies reactive with proteins of the host bacteria, and subsequently absorbed on an affinity column coupled with 1.5 mg/ml purified fusion protein. After extensive washing with 0.5 M NaClllO mM Tris, pH 7.5, the antibodies were eluted with 0.1 M glycine, pH 2.5, followed by 0.1 M triethylamine, pH 11.5. Eluted fractions were immediately neutralized with 0.1 vol 1 M Tris, pH 7.5. The purified antibodies were pooled and precipitated by addition of (N&)zS04 to 50% saturation and resuspended in TBS/l% BSA/O.O2% sodium azide. Preimmune control serum was treated analogously.
Tissue Staining. Cryosections of normal human tissues 5 pm thick were fixed with acetone and air-dried. For immunohistochemical stainings, primary antibodies were diluted 1:50 in 3% dry milk/PBS/0.02% sodium azide and applied overnight at 4°C. Rabbit antibodies were detected using an immunoperoxidase Vectastain ABC kit (Vector Laboratories; Burlingame, CA) according to the instructions of the manufacturer. The sections were subsequently counterstained with Mayer's hematoxylin solution for 1 min.
Three different control reactions were performed to confirm the specificity of the immunostaining reactions: (a) processed preimmune serum was used in place of the primary antibodies; (b) the primary antibody binding step was omitted; or (c) the primary antibody binding was blocked by adding 20 pg/ml soluble fusion protein to the antibody solution before incubation.
Some cryosections were stained for comparative purposes with the monoclonal antibody CIV 22 against human collagen IV (Odermatt et al., 1984) .
In those experiments, hybridoma culture supernatant diluted l:30 was used.
Standard elastica-van Gieson staining was performed to distinguish the elastic fiber network.
Results
Our study of the normal distribution of versican in adult human tissues reveals that the large chondroitin sulfate PG versican is not confined to connective tissues only. Immunoreactivity was also detected in smooth muscle tissues, in epithelial layers, and in the nervous system. Table 1 summarizes the results of our immunohistochemical survey and lists the versican distribution according to tissue types. A detailed description of the versican localization in specific tissues and organs follows below.
Cardzovascuiar System
Between the versican-negative heart muscle cells, a network of versican-positive capillaries was detected ( Figure la ). In addition, larger blood vessels gave rise to a diffuse staining pattern with the anti-versican antibodies. All the three tissue layers (tunica intima, Versican was also present around blood capillaries, with the exception of the capillaries in the kidney glomeruli ( Figure Ig) and liver sinus (Figure 2k ).
Lymphatic Organs
In spleen, the intense venican staining was confined to the connective tissue of the capsule and around central arterioles ( Figure  li ). Versican immunoreactivity was never detected in association with lymphatic cells either in spleen or in lymph nodes, tonsils, or other organs.
Supporting Tissues
In tendon, the parallel array of thick collagen fibers did not contain any venican immunoreactivity (Figure 2a ). The positive foci intermingled between these fibers most probably originate from fibrocytes and the capillary network.
Versican was completely absent from extracellular matrix and cells of hyaline cartilage from the rib and trachea (Figure 2b) , with the exception of the perichondrial matrix. In contrast, positive clusters of chondroyctes with intra-and pericellular staining patterns were noted in the elastic cartilage tissue of the epiglottis (Figure 2c ) and in the fibrous cartilage of the intervertebral discs (not shown).
No versican staining was observed in association with skeletal muscle fibers ( Figure 2d ). The versican positivity was restricted to endo-, peri-, and epimysium. The endomysium of the intrafusal muscle fiben ofthe muscle spindle appeared to be particularly rich in versican (Figure 2d ).
Because only frozen sections could be examined with our polyclonal antibody, we were not able to analyze the distribution of versican in bone.
Skin and Breast Tirssles
The expression of versican by keratinocytes and dermal fibroblasts has been subjected to an extended investigation, which we published previously . However, to provide a complete overview of the versican distribution in adult human tissues, we have also included data from skin in this report. Briefly, intense versican staining was observed along the keratinocyte proliferation zone in the basal cell layer of the epidermis (Figure ze) , including the sheaths of the hair follicles. In the dermis, versican was associated with the elastic network. Elastic fibers of all calibers, including elaunin and oxytalan fibers, displayrd versican immunoreactivity.
In the breast, connective tissues around the lobules and ducts gave rise to a weak immunoreactivity with anti-versican antibodies (not shown). In fibrotic regions, the thick versican-negative collagen bundles were separated by focally positive extracellular matrix. No staining was noted in the epithelial component of this tissue.
Gastrointestinal Tract
In squamous, nonkeratinizing epithelia of tongue and esophagus, staining with the antibodies against versican was not always consistent. In most areas of these organs versican was absent from the epithelia (Figure 2f ). However, in a few sections versican staining was also observed in the basal epithelial cell layer. In the proximal esophagus, versican was noted in the smooth muscle tissue ( Figure  2g ). In contrast, intermixed striated muscle fibers displayed no versican immunoreactivity, with the exception of the endomysium. In the mucosa of the stomach and of small and large intestine, versican was absent in the goblet and columnar cells, whereas the surrounding connective tissue strongly stained with the anti-versican antibodies (Figure 2h ). Versican was also present in both muscular layers of the intestine, the muscularis mucosae (Figure 2h ), and the muscularis propria (Figure 29 . In the muscularis propria, the distribution of versican was associated with the connective tissue separating the muscle fascicles from leading blood vessels. However, the versican distribution was clearly different from the basement membrane staining pattern obtained with an anti-collagen IV antibody (Figure 2j ). The groups of versican-negative ganglion cells of the vegetative submucosal plexus of Meissner and the myenteric plexus of Auerbach were encased by a narrow layer of versican containing connective tissue (Figure 2i ).
In the liver, distinct staining with anti-versican antibodies could be observed in connective tissues of the portal tracts (not shown), whereas the epithelia of the bile ducts were negative. A weak im- (1) In contrasl, the nonkeratinizing squamous epithelium of the esophagus displays no VC staining, whereas the subepithelial connective tissue is highly immunoreactive. (9) VC is also present in the smooth and striated muscle tissues of the proximal esophagus. (h) The smooth muscle cell layers of the muscularis mucosae of small intestinal villi display strong immunostaining with the anti-VC antibodies.
However, VC is not detected in the simple columnar epithelium of the villi. The distribution of VC in the muscularis propria of the colon (I) is clearly distinct from the basement membrane staining pattern U) of a monoclonal antibody against collagen IV (C IV). VC is also observed in liver bile canaliculi (k) but is absent from the liver sinus capillaries, revealed by comparison with a collagen IV staining (I). Whereas VC is not detected in the stratified columnar epithelium of the trachea (m), strong immunoreaction is seen in the underlying stromal tissue and in the elastic network of the lung alveoli (n). VC staining is also present in the subcapsular connective tissue and the zona glomerulosa of the adrenal cortex (0) and on the apical surface of the thyroid follicles (p). Bars = 50 wm. munoreaction was detected along the bile canaliculi (Figure 2k ). However, versican was absent from the cytoplasm of the hepatocytes and from the collagen IV-positive liver sinus (Figures 2k and 21) . In pancreas, versican was localized in the connective tissues surrounding the exocrine acini, and in various ducts and blood vessels (not shown). No staining was observed in the islets of Langerhans.
Respiratory Tract
Versican was completely absent from the epithelial components of the lungs, bronchi, trachea (Figure 2m ), and larynx, but intense staining of the subepithelial connective tissues was noted. In the alveolar walls of the lungs, versican co-localized with the fine fibers of the elastic network (Figure 2n ). In analogy to the veins of the systemic circulation, versican was present in all layers of the pulmonary veins (not shown). In the lung arteries, thickening of the intima was accompanied by the appearance of versican immunoreactivity in the intima and the underlying tunica media (not shown). The versican staining properties of cartilage, vessels, and nerves in the respiratory tract were identical to analogous tissues described in other sections of this article.
Endocrine Organs
The connective tissue surrounding the cells of all three zones of the adrenal cortex contained versican. The staining intensity was clearly increased in the subcapsular region and in the zona glomerulosa ( Figure 20) . In the medulla of the adrenal gland, the versican staining was noted along the blood vessels, whereas the medullary cells themselves were versican-negative.
In the thyroid, weak focal versican staining was observed at the luminal surface of thyreocytes ( Figure 2p ) and in the subepithelial connective tissue (not shown). The latter immunoreactivity was more prominent in regressively transformed regions of the thyroid.
In the adenohypophysis, only the delicate network of connective tissue and capillaries surrounding nests and cords of endocrine cells contained versican (not shown).
Urinary Tract
In the bladder and the ureter, versican-containing layers of connective tissue and smooth muscles were covered by versican-negative transitional epithelium (Figure 3a) .
In the kidney, the glomeruli (Figure lg ) and the various types of tubules did not stain with the polyclonal antibodies against versican. However, versican was present in the surrounding connective tissue, with more pronounced staining around regressively transformed glomeruli.
Female Genital Eact
In the ovary, versican was present in the large blood vessels of the medulla, whereas no staining could be detected in stromal cells and in the surface epithelium (not shown). The smooth muscle layers of the uterus (Figure 3b ) and the Fallopian tube showed a diffuse immunoreactivity. The glands of the endometrium and the endocervix were composed of versican-negative epithelial associated with weak versican staining in the underlying stroma. In addition, the squamous epithelium of the exocervix and the vagina (Figures  3c and 3d ) did not react with antibodies against versican. In contrast, a strong immunoreaction was observed in the dense plexus of elastic fibers beneath the epithelium of the vagina (Figure 3c ).
In the placenta, versican was localized in the villous mesenchyme and around blood vessels, whereas the trophoblasts lining the villi displayed no versican staining (Figure 3e ).
Male Genital Tract
In the testis, versican was restricted to the tunica propria surrounding seminiferous tubules (Figure 3f ). Germ cells, Sertoli as well as Leydig cells, were versican-negative. The wall of the ductus deferens consisted of diffusely positive, thick smooth muscle layers with the versican-negative luminal columnar epithelium (not shown).
A similar staining pattern was observed in the prostate ( Figure   3g ). However, a strong linear versican immunoreaction was also observed at the apical surface of the columnar cells of the prostate epithelium. The specificity ofthis reaction was documented by control experiments in which the antibody binding was completely abolished by addition of 20 pg/ml recombinant versican fragment to the first antibody solution (Figure 3h ).
Perz$heral and Central Nervous System
In the peripheral nervous system, nerves were surrounded by versican-positive perineurium (Figure 3i ). Within the nerves, a focal immunoreaction with anti-versican antibodies was observed, which most probably corresponds to capillaries or fibrocytes of the endoneurium.
To study the distribution of versican in the central nervous system, sections from the frontal lobe (Figures 3j-31 ). the cerebellum (Figures 3m and 3n) , and brainstem (Figures 30 and 3p) . and from the spinal cord (not shown) were examined. Particularly in the white matter, the versican immunostaining (Figures 3k and 30) was very similar to the pattern obtained with antibodies against glial fibrillary acidic protein (not shown), thus suggesting a close association of versican expression with astrocytes. Versican was also present in the submeningeal layer of the cortex (Figure 3j granular cell layer of the cerebellum. (0) In the brainstem, the blood vessel-and glial cell-associated immunoreactivity with anti= antibodies is evident. Negative control sections (neg) of vagina, prostate, cerebellum, and brainstem are displayed in d, h. n, and p. respectively. Bars = 50 pm. vessels (Figures 31 and 30) . In none of the tissues tested was staining of neurons with the versican VOIV1-specific antibodies observed. In the cerebellum, diffuse versican positivity was also detected in the molecular layer (Figure 3m ). This staining was completely absent from control sections in which the first antibody reaction was omitted (Figure 3n ).
Discussion
The generation of monospecific antibodies against large aggregating PGs has been rather difficult because of their high content of common carbohydrate structures and because of extensive sequence similarities within the globular core protein domains. Comparisons of the primary structures of human versican with rat neurocan, bovine brevican, and human aggrecan have revealed sequence identities within the Cand N-terminal domains that reached almost 70% (Yamada et al., 1994) . In consequence, immunization with intact PG molecules bore the risk that the antibody preparations would recognize shared peptide epitopes and/or carbohydrate structures and hence could crossreact with other PG species. In our recent approach to preparing polyclonal antibodies against human versican , we circumvented these problems by immunizing rabbits with a recombinant polypeptide fragment that contained only unique versican sequences. Except for the chick and mouse versican homologues, no similarities to aggrecan, neurocan, brevican, or to any other known protein sequences were contained in this fragment. Furthermore, to avoid potential epitope masking by chondroitin sulfate side chains that are covalently bound in intact versican, the fragment was chosen from a core protein portion that lacked putative GAG attachment sites. Therefore, the purified polyclonal antibodies reacted specifically with the core proteins of the versican splice variants VO and V1 even without chondroitinase ABC treatment of the cryosections.
Our immunohistochemical survey of versican localization in adult human tissues revealed the widespread distribution of this large aggregating PG. The immunohistochemical data are in good agreement with our recent reverse transcription-PCR study (Dours-Zimmermann and Zimmermann, 1994) , in which we amplified versican VO-and VI-specific mRNA fragments from intervertebral disc, aorta, myometrium, prostate, liver, and cerebral cortex. In vitro, versican-specific mRNAs had been detected in fibroblasts from various origins Shinomura et al., 1993; Kahari et al., 1991; Krusius et al., 1987) . in arterial smooth muscle cells (Schonherr et al., 1991) , in aortic endothelial cells (Ito et al., 1995) , and in keratinocytes , as well as in cultures of MG63 osteosarcoma (Krusius et al., 1987) and U251MG glioma cell lines (Dours-Zimmemann and Zimmermann, 1994) . In line with these observations, Naso et al. (1994) demonstrated that the promoter of the versican gene is highly functional in transiently transfected cells of both mesenchymal and epithelial origin. Our data on the distribution of the versican core protein within connective tissues, smooth muscle cell layers, in the epidermis, and in association with the nervous system now suggest that cells different from fibroblasts are also able to express versican in vivo.
In the elastic tissues, a close association of versican with elastic fibers and laminae was evident. The versican staining generally mir-rored the distribution of elastin, fibulin-1 (Roark et al., 1995) , and the microfibril-associated glycoproteins MAGP (Kumaratilake et al., 1989) and fibrillin-1 (Sakai et al., 1986) . However, there were notable exceptions: versican was completely absent from the media and elastica interna of normal muscular arteries and from the elastin-free microfibrillar matrix surrounding the mesangial cells in the kidney glomeruli. Interestingly, glomerular mesangial cells do synthesize a versican-like PG in vitro (Thomas et al., 1994) . The discrepancy from the in vivo situation might be explained by the possibility that mesangial cells express versican only during active cell proliferation.
In the context of the versican localization in elastic tissues, the particular distribution in blood vessel walls must be emphasized. Versican was found around all types of blood vessels, ranging from the large-caliber aorta and vena cava to the smallest capillaries. Only the capillaries of the kidney glomeruli and the liver sinus were not associated with versican immunoreactivity. The absence of versican around these capillaries may be linked to their specialized function in substance exchange. In muscular arteries, the appearance of versican in intimal and medial layers correlated with the thickening of the luminal vessel wall in early atherosclerotic lesions. An enrichment of versican or versican-like PGs had previously been noted in the hyperplastic intima of atherosclerotic rabbit aortas (Lark et al., 1988) and in the neointimal tissue of rat carotids after balloon injury (Wolf et al., 1994) . The upregulation of versican expression appeared to be controlled by TGF-p andlor PDGF, as in vitro experiments with arterial smooth muscle cells demonstrated that addition of TGF-b or PDGF to the culture medium resulted in a threefold increase in versican mRNA levels (Schonherr et al., 1991) . Furthermore, administration of neutralizing anti-KF-0 antibodies to rats after balloon injury significantly reduced both the size of the neointimal lesions and the expression of versican (Wolf et al., 1994) . Because the accumulation of proteoglycans has been regarded as one of the key events in early plaque formation (reviewed by Wight, 1989) , the upregulation of versican expression in hyperplastic vessel walls may be of great importance in the initial steps of atherosclerosis.
Versican VO/V1 was also present around capillaries in the central nervous system. Two types of cells may be responsible for the occurrence of versican at this location: endothelial cells covering the lumen of the blood vessel or astrocytes that contact the capillaries with their processes. It seems likely that both cell types express versican in neural tissues, as endothelial (Ito et al., 1995) and glial cells (Dours-Zimmermann and Zimmermann, 1994) synthesize versican in vitro. A mainly astrocytic origin of versican in brain tissues is suggested by the capillary-independent staining pattern that strongly resembles the picture obtained with antibodies against the astrocyte marker GFAP. Although our immunohistochemical data provide no evidence for expression of versican VOlVl isoforms by neurons or other glial cells, we cannot rule out the possibility that these cells synthesize versican V2. The mRNA coding for this smaller versican splice variant appears to be expressed exclusively in brain tissues, but it is not present in a glioma cell line of astrocytic origin (Dours-Zimmermann and Zimmermann, 1994) . Because our anti-versican antibodies recognize GAG-P-specific epitopes, an eventual expression of the V2 isoform by neurons or oligodendrocytes would evade immunohistochemical detection.
A rather intriguing immunoreactivity with the anti-versican antibodies was observed on the apical pole of hepatocytes and in thyroid and prostate epithelia. Interestingly, seminal vesicles and prostate ducts secrete hyaluronan, a versican ligand, into the seminal fluid (Tammi et al., 1994; Geipel et al., 1992) . Hyaluronan and a large chondroitin sulfate P G from follicular fluid both improve the retention of sperm motility and velocity in vitro (Eriksen et al., 1994; Huszar et al., 1990) . Although versican may have a similar function, we d o not know to date whether the prostate epithelium indeed secretes versican into the seminal fluid.
The highly diversified distribution of versican in normal adult tissues may reflect the functional versatility of this large aggregating PG. Several lines of evidence point to a putative role of versican in destabilizing cell-matrix interactions. For example, immobilized versican interferes in vitro with the adhesion of chick fibroblasts to fibronectin, collagen I, laminin, and vitronectin (Yamagata et al., 1989) . Accordingly, endogenous versican is excluded from focal contacts that mediate the attachment of cells to extracellular substrates (Yamagata et al., 1993) . During embryonic development, versican is expressed in tissues that form barriers to migratory neural crest cells and outgrowing axons (Landolt et al., 1995) . Such interaction-inhibiting properties may result from simple steric hindrance, in which the large and highly hydrated versican molecule locally separates two potential ligands, or they may originate from a complex signaling process similar to the one suggested for a neurocan-like PG (Balsamo et al., 1995) . It appears conceivable that versican acts through both of these mechanisms. In the elastic network, it may add to the elasticity by simply preventing the fibers from sticking to each other, whereas it may modulate in a more complex fashion cell-cell and cell-matrix interactions in areas of cell migration and proliferation.
Pursuing the concept that versican actively participates in the control of cell adhesion, migration, and proliferation, it seems appropriate to investigate the expression of versican in pathological processes, such as tumor progression and metastasis, and in the development of atherosclerotic lesions. Our inventory of the versican distribution in normal adult tissues will now form the basis for these future studies.
